Discussion: In addition, emergence of resistance SARS-CoV-2 mutations, such as D484Y in RdRp, have been reported following failure of remdesivir treatment in an individual with B-cell immunodeficiency due to lymphocytic leukemia treated by rituximab.
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.
Result: A mutation at D484Y has been reported in a post- treatment sample from an immunocompromised patient who failed RDV therapy, but the RDV resistance phenotype associated with this mutation, whose location is distal to the active site, has not been confirmed.
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
Abstract: We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia.
SARS-CoV-2 mutations: the biological trackway towards viral fitness.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Microorganisms
Browser Board
Co-occurred Entities
Filtrator
ViMRT